Results 111 to 120 of about 1,643 (210)
Allergy, EarlyView.ABSTRACT In the last decades, critical advancements in research technology and knowledge on disease mechanisms steered therapeutic approaches for chronic inflammatory diseases towards unprecedented target specificity. For allergic and chronic lung diseases, biologic drugs pioneered this goal, acquiring on the way—through the clinical use of monoclonal ...
F. Roth‐Walter +20 more
wiley +1 more source
Dietary Habits and Atopic Dermatitis Significantly Influence the Fecal Microbiome
Allergy, EarlyView.Atopic dermatitis, dietary habits, sex, and BMI significantly influenced the fecal microbiome composition. On the species level, Faecalibacterium taiwanense was more abundant in atopic dermatitis, and Vescimonas sp000435555 was more abundant in the control population. On the genus level, CAG‐302 (NCBI: Clostridium) was more abundant in controls.
Danielle Fehr +14 more
wiley +1 more source
Allergy, EarlyView.ABSTRACT These updated EAACI guidelines aim to standardize skin testing methodologies for both immediate and non‐immediate drug hypersensitivity reactions. For immediate reactions, the optimal testing window is 4–6 weeks post‐reaction; whereas beyond 6 months, false‐negative results increase.
Annick Barbaud +14 more
wiley +1 more source
Acta Ophthalmologica, EarlyView.Abstract Purpose To assess the impact of biosimilar ranibizumab and on‐patent faricimab market entry on pricing and utilization trends and describe national variation in off‐label bevacizumab use in Europe. Methods Interrupted time series analysis of quarterly sales data (Q1 2018–Q2 2024) in 11 European countries evaluated ranibizumab utilization and ...
Elif Car +3 more
wiley +1 more source
Review Article: The Impact of the Gut Microbiome on Ulcerative Colitis Pharmacotherapy
Alimentary Pharmacology &Therapeutics, EarlyView.The gut microbiome modulates ulcerative colitis pharmacotherapy through microbial drug metabolism, immune regulation and altered drug bioavailability. Microbial composition influences response to aminosalicylates, corticosteroids, immunomodulators, biologics and small molecules, while microbiome‐targeted therapies show emerging promise.
Kate Collins +6 more
wiley +1 more source
British Journal of Haematology, EarlyView.Selinexor targets molecular pathways critical to myelofibrosis (MF) progenitor cell fitness and demonstrates complementary activity with ruxolitinib, supporting its potential as a novel disease‐modifying therapeutic strategy for MF. Summary Myelofibrosis (MF) is a chronic myeloproliferative neoplasm (MPN) characterized by splenomegaly, constitutional ...
Trinayan Kashyap +7 more
wiley +1 more source
British Journal of Haematology, EarlyView.Summary Over the past decade, there has been a substantial increase in the diversity and number of therapeutic options for myeloproliferative neoplasms (MPNs). While many remain within the clinical trial arena, the clinician and patient community have seen more approvals reaching the clinic and a rethink on how best we should be approaching these ...
Trung Q. Ngo +3 more
wiley +1 more source
British Journal of Haematology, EarlyView.Summary Targeting the colony‐stimulating factor 1 receptor (CSF1R) to remove tumour‐associated macrophages is being explored as cancer therapy. This strategy may be relevant for chronic lymphocytic leukaemia (CLL), which strongly depends on support from myeloid cells.
Natascha Rosen +14 more
wiley +1 more source
Survival outcomes and treatment patterns in myelofibrosis in the JAK inhibitor era
British Journal of Haematology, EarlyView.Summary Data on real‐world survival and treatment patterns in large, unselected myelofibrosis (MF) cohorts remain limited. We analysed 1649 patients with MF diagnosed from 2010 onwards and included in the Spanish Myelofibrosis Registry across 64 centres. Janus kinase (JAK) inhibitors were administered to approximately half of the patients.
Juan‐Carlos Hernández‐Boluda +35 more
wiley +1 more source